UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section
13 or 15(d) of the Securities Exchange Act of 1934
Date
of report: April 27, 2007
Date of earliest event reported: April 27, 2007
PFIZER
INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
1-3619
(Commission File Number)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive
offices) (zip code)
(212) 573-2323
(Registrant's telephone number)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the obligation of the registrant under any
of the following provisions:
[ ] Written communication pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01. Other
Events
Exhibit 100 to this Current
Report on Form 8-K contains documents formatted in XBRL (eXtensible Business
Reporting Language) with information from Pfizer Inc.'s Annual Report on
Form 10-K for the year ended December 31,
2006, filed with the Securities and
Exchange Commission (SEC) on March 1, 2007. The information formatted in XBRL
includes the (i) Consolidated Statements of Income for the years ended December
31, 2006, 2005 and 2004, (ii) Consolidated
Balance Sheets at December 31, 2006 and 2005, (iii) Consolidated Statements of Cash Flows for the
years ended December 31, 2006, 2005 and 2004, and (iv) the Consolidated Statements
of Shareholders' Equity for the years ended December 31, 2006, 2005 and 2004.
Users of this data are
advised pursuant to Rule 401 of Regulation S-T that the financial information
contained in the XBRL-Related Documents is unaudited and these are not the official
financial statements of Pfizer Inc. as filed with the SEC. The purpose of
furnishing these XBRL formatted documents is solely for the purpose of participation
in the SEC's voluntary XBRL pilot program to test the related format and
technology and, as a result, investors should continue to rely on the official
filed version of the furnished documents and not rely on the information in
this Current Report on Form 8-K, including Exhibit 100, in making investment
decisions.
In accordance with Rule
402 of Regulation S-T, the information in this Current Report on Form 8-K,
including Exhibit 100, shall not be deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liability of that section, and shall
not be incorporated by reference into any registration statement or other
document filed under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial
Statements and Exhibits.
(d)
Exhibits
The following exhibits are
furnished herewith:
Exhibit Number
Exhibit Description
100
The following financial
statements from Pfizer Inc.'s Annual Report on Form 10-K for the year ended
December 31, 2006, filed on March 1, 2007, formatted in XBRL (eXtensible
Business Reporting Language): (i) the Consolidated Statements of Income
for the years ended December 31, 2006, 2005 and 2004, (ii) the
Consolidated Balance Sheets at December 31, 2006 and 2005, (iii) the Consolidated Statements of Cash Flows for the